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Abstract: This study was designed to investigate the therapeutic effect and mechanisms of action of novel 
compound N-(Z)-9-octadecenyl-2-propanesulfonamide (N15) on type 2 diabetes (T2DM).  A mouse model of 
T2DM was established with multiple injection of streptozotocin (STZ) at a low dose.  N15 at different doses (50, 
100 and 200 mg·kg−1·d−1) and pioglitazone (6 mg·kg−1·d−1) were administrated orally for 6 weeks.  The level of 
fasting blood glucose (FBG) and fasting insulin (FIns) were measured in the course of the experiment for insulin 
resistance index (HOMA-IR).  Oral glucose tolerance test (OGTT) and intraperitoneal insulin tolerance test 
(IPITT) were determined in the treated mice.  The expression of Akt, AMPK and Glut4 in liver were analyzed       
by Western blot.  N15 was found to reduce the level of FBG, FIns and HOMA-IR (P < 0.01) and ameliorate       
the glucose and insulin tolerance (P < 0.01, P < 0.001).  Simultaneously the protein expression of p-Akt, 
p-AMPK and Glut4 was significantly increased in liver by N15 (P < 0.01).  These effects were similar to those 
of pioglitazone (P > 0.05).  These results suggested that the novel compound N15 can ameliorate insulin       
resistance and the potential mechanism may be associated with increased insulin signaling in liver and promotion 
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of phosphatidyl inositol 3 phosphate phosphorylation. 
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Figure 1  The structures of oleoylethanolamid (OEA) and N-   
(Z)-9-octadecenyl-2-propanesulfonamide (N15) 
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Table 1  The fasting blood glucose (FBG), fasting blood insulin 
(FIns) and homeostasis model assessment-insulin resistance index 
(HOMA-IR) in model mice were observed.  n = 10, mean ± SEM.  
#P < 0.05, ###P < 0.001 vs normal group 
Group FBG FIns HOMA-IR 
Normal  5.316 ± 0.937  5.100 ± 1.699  1.343 ± 0.708 
Model 13.416 ± 1.614###  5.567 ± 0.317#  3.320 ± 0.443###
 
2  N15 ?????? FBG?FIns ? HOMA-IR ?
???
????, ??????, 50? 100 mg·kg−1·d−1 
N15??? FBG?FIns? HOMA-IR????? (?
2A?C, P < 0.001), FBG?FIns?? 7??????? 
(? 2A?B, P < 0.001), HOMA-IR?? 28?????
?? (? 2C, P < 0.001)??? 7 ? 14 ?? (? 2A, 
P<0.05, P < 0.01), 200 mg·kg−1·d−1 N15??? FBG      
???????????? (? 2A, P > 0.05), ?
14?28? 42? FIns????? (? 2B, P < 0.001), 
HOMA-IR?? 42??????? (? 2C, P < 0.001)?
???????? , N15 ???????? 100 
mg·kg−1·d−1????????????????, N15
??? FBG?FIns? HOMA-IR??????? (?
2A?C, P > 0.05)? 
3  N15?????????????????????
??????????????????? 3A?
B??, ??????, 100? 200 mg·kg−1·d−1 N15
?????? 2????????????????
??? (P < 0.05, P < 0.01, P < 0.001); 50 mg·kg−1·d−1 
 
 
Figure 2  Effect of N15 (50, 100 and 200 mg·kg−1·d−1) on glycaemic control in KM mice, pioglitazone (6 mg·kg−1·d−1) as the positive 
group.  A: Sequential monitoring of FBG; B: FIns; C: HOMA-IR, after 8 h fasting.  n = 10, mean ± SEM.  ##P < 0.01, ###P < 0.001 vs 
normal group; *P < 0.05, **P < 0.01, ***P < 0.001 vs model group 
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Figure 3  N15 ameliorates glucose and insulin tolerance in KM mice.  Oral glucose tolerance test (OGTT) (A) and intraperitoneal 
insulin tolerance test (IPITT) (B) were preformed after 8 h fasting.  Plasma glucose and insulin levels were measured from the blood 
samples that were drawn at baseline (t = 0 min) and indicated time points.  n = 10, mean ± SEM.  ##P < 0.01, ###P < 0.001 vs normal group; 
*P < 0.05, **P < 0.01, ***P < 0.001 vs model group 
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Figure 4  Effect of N15 on Akt, AMPK and Glut4 activity in liver.  A: Representative Western blot images of p-Akt, Akt, p-AMPK, 
AMPK and Glut4 protein; B−D: Quantitative analysis of p-Akt/Akt, p-AMPK/AMPK and Glut4.  The values are expressed as percen-
tages compared with the normal group (set to 100%).  n = 10, mean ± SEM.  ##P < 0.01 vs normal group; **P < 0.01 vs model group 
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Figure 5  Mechanism of N15 on hepatocyte in type 2 diabetic 
mellitus 
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